What Is Jaundice In Babies Causes Symptoms And Management

Published

Table of Contents

Jaundice in newborns is a common yet medically significant condition characterized by the yellowing of skin and eyes due to elevated bilirubin levels, a byproduct of red blood cell breakdown. While often harmless in physiological forms, severe or prolonged jaundice can signal underlying complications requiring prompt intervention. Understanding its mechanisms—from bilirubin metabolism to risk factors—enables parents and caregivers to recognize early signs and differentiate between transient and pathological cases.

The condition typically emerges within the first few days of life as the infant’s liver adapts to processing excess bilirubin, a process influenced by factors such as prematurity, breastfeeding challenges, or genetic predispositions. Physiological jaundice, the most frequent variant, resolves spontaneously, whereas pathological jaundice demands medical evaluation to prevent potential neurological damage. This overview explores the physiological pathways, diagnostic tools, and critical thresholds that distinguish benign from concerning presentations, equipping readers with actionable insights for timely care.

what is jaundice in babies

Definition and Physiological Mechanisms of Jaundice in Newborns

Jaundice in newborns is a common condition characterized by the yellowish discoloration of the skin, mucous membranes, and sclera (whites of the eyes) due to elevated levels of bilirubin, a yellow pigment produced during the breakdown of red blood cells (RBCs). While often benign in healthy term infants, excessive bilirubin accumulation can indicate underlying metabolic or pathological conditions requiring medical intervention. The condition arises primarily from an imbalance between bilirubin production, conjugation, and excretion, with physiological jaundice being the most frequent variant in the neonatal period.

The development of jaundice stems from the natural breakdown of fetal hemoglobin, which has a shorter lifespan than adult hemoglobin. During the first days of life, the liver undergoes a transition from processing fetal hemoglobin to adult hemoglobin, temporarily overwhelming its bilirubin-processing capacity. This is further exacerbated in premature infants, whose livers are less mature, and in breastfeeding infants due to delayed meconium passage and reduced caloric intake affecting gut motility.

Physiological Process of Bilirubin Metabolism in Newborns

Bilirubin metabolism involves three critical stages: production, conjugation, and excretion. In healthy newborns, red blood cells (RBCs) undergo hemolysis at the end of their lifespan (~120 days in adults, but shorter in neonates), releasing hemoglobin. Hemoglobin is then broken down into unconjugated bilirubin (indirect bilirubin), a lipid-soluble compound that binds to albumin for transport to the liver. Within hepatocytes, bilirubin undergoes conjugation via uridine diphosphate-glucuronosyltransferase (UGT1A1), transforming it into water-soluble conjugated bilirubin (direct bilirubin), which is excreted into bile and eliminated via feces. In jaundiced neonates, disruptions at any stage—particularly overproduction (excess RBC breakdown) or impaired conjugation (immature liver enzymes)—lead to hyperbilirubinemia.

The following table illustrates the bilirubin cycle in healthy vs. jaundiced newborns, highlighting key differences in liver function and RBC turnover:

Stage Healthy Newborn Jaundiced Newborn (Physiological) Pathological Disruption
Red Blood Cell Breakdown Moderate hemolysis; fetal hemoglobin (HbF) declines over 6–8 weeks. Accelerated hemolysis due to shorter RBC lifespan (HbF breakdown). Excessive hemolysis (e.g., ABO/Rh incompatibility, hereditary spherocytosis).
Unconjugated Bilirubin Transport Bound to albumin; efficiently delivered to liver. Albumin binding capacity may be overwhelmed; transient "free bilirubin" spikes. Reduced albumin levels (e.g., preterm birth, sepsis) or displacement by drugs.
Liver Conjugation UGT1A1 activity increases postnatally; bilirubin conjugated to glucuronides. Delayed UGT1A1 maturation in preterm infants; slower conjugation. Genetic UGT1A1 deficiency (Crigler-Najjar syndrome) or liver disease.
Bile Excretion and Gut Elimination Conjugated bilirubin excreted into bile; converted to urobilinogen by gut bacteria. Reduced gut motility (breastfeeding) or delayed meconium passage slows excretion. Biliary obstruction (e.g., biliary atresia) or gut malabsorption.
Reabsorption (Enterohepatic Circulation) Minimal reabsorption; urobilinogen excreted in urine/feces. Prolonged enterohepatic circulation in breastfeeding infants. Gut ischemia or bacterial overgrowth increasing reabsorption.
Key Insight:
In physiological jaundice, the liver’s bilirubin-processing capacity is temporarily insufficient due to immature UGT1A1 enzyme activity and high RBC turnover, particularly in preterm or breastfeeding infants. Pathological jaundice, however, involves structural liver dysfunction, hemolytic disorders, or systemic conditions that disrupt bilirubin clearance beyond normal neonatal adaptation.

Differentiating Physiological vs. Pathological Jaundice

While most neonatal jaundice resolves spontaneously, distinguishing between physiological (self-limiting) and pathological (requiring intervention) forms is critical. The following table outlines key distinguishing factors, emphasizing clinical red flags that warrant immediate medical evaluation:

what is jaundice in babies - Ilustrasi 2

Symptoms, Stages, and Progression of Jaundice in Newborns

Jaundice in newborns is primarily identified through observable skin and eye discoloration, alongside clinical indicators that vary in severity. While visual symptoms are the most common markers, non-visual signs—such as altered behavior and physiological distress—often signal underlying complications requiring immediate medical intervention. The progression of jaundice follows a predictable pattern tied to bilirubin accumulation, with distinct stages demarcated by bilirubin levels and anatomical spread. Understanding these manifestations enables timely diagnosis and intervention, particularly in high-risk infants.

Visual assessment remains the cornerstone of jaundice detection, though lighting conditions and skin pigmentation influence accuracy. Non-visual symptoms, though less apparent, serve as critical red flags for severe hyperbilirubinemia, necessitating structured monitoring protocols.

Visual Symptoms and Progression Patterns

The hallmark of neonatal jaundice is a yellowish discoloration of the skin and sclera (whites of the eyes), resulting from bilirubin deposition. The progression follows a cephalocaudal (head-to-toe) sequence, beginning in areas with thinner skin and higher vascularity. Lighting conditions significantly impact visibility:
  • Natural daylight or fluorescent lighting enhances yellow hue detection, whereas incandescent or dim lighting may obscure subtle changes.
  • Dark-skinned infants exhibit jaundice as a greenish-yellow tint, particularly noticeable in the palms, soles, and mucous membranes (e.g., gums, inner eyelids).
  • Premature or low-birth-weight infants may show jaundice earlier (within 24 hours) and with lower bilirubin levels due to immature liver function.

    • The progression stages are as follows:
    1. Mild jaundice: Limited to the face, forehead, and upper chest, often missed in darker-skinned babies or under poor lighting.
    2. Moderate jaundice: Extends to the abdomen, arms, and thighs, with noticeable yellowing of the sclera and oral mucosa.
    3. Severe jaundice: Spreads to the hands, feet, and palms/soles, accompanied by greenish discoloration in advanced cases. This stage correlates with bilirubin levels exceeding 15–20 mg/dL in term infants and 12–15 mg/dL in preterm infants.

    Non-Visual Symptoms by Severity Level

    While visual cues are primary, non-visual symptoms indicate systemic stress and potential complications, particularly when jaundice is severe or rapidly progressing. These symptoms are categorized by severity to guide clinical urgency:

    Importance of Non-Visual Signs
    Non-visual symptoms often precede visible deterioration and may reflect kernicterus risk (bilirubin-induced brain damage). Early recognition of lethargy, feeding difficulties, or abnormal crying can prompt interventions such as phototherapy or exchange transfusion before irreversible neurological sequelae occur.

    - Mild (Bilirubin: <12 mg/dL)

  • Lethargy or mild irritability during feeding or diaper changes.
  • Poor suckling or brief pauses during breastfeeding, attributed to mild discomfort.
  • Slightly high-pitched cry (non-sustained), possibly due to abdominal discomfort from bilirubin accumulation in tissues.

    • - Moderate (Bilirubin: 12–18 mg/dL)

  • Prolonged lethargy (e.g., difficulty waking for feeds, excessive sleeping).
  • Arching of the back or stiffening during handling, suggesting neurological irritation.
  • Poor weight gain or fewer wet diapers (≤4 per day) due to dehydration or metabolic stress.
  • High-pitched, shrill cry persisting beyond feeding episodes, indicative of central nervous system involvement.

    • - Severe (Bilirubin: >18 mg/dL)

  • Seizures or tremors (e.g., rhythmic jerking of limbs, opisthotonos—backward arching).
  • Apnea or bradycardia (irregular breathing or heart rate <100 bpm), signaling hypoxic stress.
  • Refusal to feed or projectile vomiting, suggesting hepatic or metabolic dysfunction.
  • Hypotonia or flaccidity, with weak muscle tone and diminished reflexes (e.g., Moro or grasp reflexes).
  • Altered consciousness, such as glasgow coma scale depression (e.g., poor eye opening, abnormal responses to stimuli).

    • Stages of Jaundice by Bilirubin Levels and Clinical Thresholds

    Jaundice progression is quantified using total serum bilirubin (TSB) levels, with critical thresholds varying by gestational age and postnatal age. The following stages outline key bilirubin ranges and corresponding clinical interventions:

    1. Physiologic Jaundice (TSB: <12 mg/dL)

  • Onset: Typically appears 24–48 hours postpartum in term infants, peaking at 3–5 days.
  • Skin Changes: Yellowing limited to face, neck, and upper chest; sclera may appear white-yellow under natural light.
  • Management: Observation and breastfeeding support (mother’s milk contains substances that may enhance bilirubin excretion). Phototherapy is rarely required at this stage.
    • Physiologic jaundice is benign in most term infants but warrants monitoring in preterm or breastfed babies due to higher bilirubin loads.
    2. Pathologic Jaundice (TSB: 12–18 mg/dL)
  • Onset: May appear within 24 hours (early onset) or persist beyond 1 week (late onset), suggesting underlying causes (e.g., hemolysis, infection, or metabolic disorders).
  • Skin Changes: Extends to abdomen, arms, and thighs; sclera distinctly yellow. Greenish tint may appear in dark-skinned infants.
  • Management: Phototherapy initiation (e.g., fiberoptic blankets or bili lights) and etiological workup (e.g., blood type compatibility, direct Coombs test, sepsis screening).

    • 3. Severe Hyperbilirubinemia (TSB: >18 mg/dL)

  • Onset: Rapid rise in bilirubin, often within 48–72 hours, with kernicterus risk (brain damage) if untreated.
  • Skin Changes: Generalized yellowing to hands/feet, with greenish discoloration in advanced cases. Mucous membranes (e.g., gums, tongue) may appear jaundiced.
  • Neurological Signs: Lethargy, seizures, or hypotonia (as detailed above).
  • Management:
  • Intensive phototherapy (e.g., double phototherapy or exchange transfusion if TSB >20 mg/dL).
  • Hospitalization for continuous monitoring of bilirubin, glucose, and hydration status.
  • Exchange transfusion in extreme cases (e.g., TSB >25 mg/dL or rising despite interventions).
    • Bilirubin levels >20 mg/dL in term infants or >15 mg/dL in preterm infants require immediate intervention to prevent acute bilirubin encephalopathy (ABE).

    Timeline of Jaundice Onset, Peak, and Resolution

    The temporal pattern of neonatal jaundice varies by infant characteristics, with preterm and breastfed babies exhibiting prolonged or early-onset jaundice. The following table summarizes typical timelines, though individual cases may deviate based on risk factors (e.g., ABO/Rh incompatibility, prematurity, or infection).
    Symptom/Feature Physiological Jaundice Pathological Jaundice When to Seek Help
    Onset Appears 24–48 hours postpartum; peaks at 3–5 days in term infants. May appear within 24 hours (early) or after 1 week (late-onset). Jaundice visible at birth or persisting beyond 2 weeks in term infants.
    Severity and Progression Mild to moderate; bilirubin < 12–15 mg/dL (varies by gestational age). Rapidly rising bilirubin (> 0.5 mg/dL/hour); may exceed 15–20 mg/dL. Yellowing spreading to feet/legs (cephalocaudal progression) or lethargy/poor feeding.
    Duration Resolves within 1–2 weeks in term infants; longer in preterm infants. Persistent beyond 2–3 weeks in term infants or worsening after initial improvement. Jaundice lasting beyond 3 weeks in full-term infants.
    Associated Symptoms No systemic symptoms; normal activity/feeding. Pallor, dark urine, pale stools, hepatosplenomegaly, or signs of infection (fever, irritability). Any signs of dehydration, vomiting, or neurological symptoms (high-pitched cry, arching back).
    Risk Factors Prematurity, breastfeeding, East Asian descent, male sex. Blood group incompatibility (ABO/Rh), hereditary hemolytic anemia, liver disease, or infections (e.g., sepsis, TORCH infections). History of family jaundice, previous sibling requiring phototherapy, or maternal diabetes.
    Bilirubin Levels Peaks at 5–6 mg/dL in term infants; < 12 mg/dL at discharge. > 15 mg/dL in term infants or > 10 mg/dL in preterm infants. Bilirubin levels approaching neurotoxic thresholds (e.g., > 20 mg/dL in term infants).
    Response to Treatment Improves with phototherapy or increased breastfeeding; no long-term sequelae. May require exchange transfusion, IVIG, or surgical intervention (e.g., biliary atresia). Failure to improve with standard phototherapy or recurrence after treatment cessation.
    Age of Baby Onset Risk Peak Severity Resolution Timeline
    Term Infant (37–42 weeks) 24–48 hours postpartum (physiologic); <24 hours or >1 week (pathologic). Days 3–5 (TSB peak: 5–6 mg/dL in term infants; higher in breastfed babies). Resolves by 10–14 days; may persist up to 3 weeks in breastfed infants.
    Late Preterm (34–36 weeks) 12–24 hours postpartum (higher risk due to immature liver conjugation). Days 2–4 (TSB peak: 8–12 mg/dL; phototherapy often required). Resolves by 2–3 weeks; prolonged jaundice (>2 weeks) warrants evaluation.
    Preterm (<3

    Risk Factors and Vulnerable Populations in Neonatal Jaundice

    Neonatal jaundice arises from a complex interplay of physiological, genetic, and environmental factors, with certain infant populations exhibiting significantly higher susceptibility. High-risk groups include premature infants, those with blood group incompatibility, and babies with inherited metabolic disorders, all of which disrupt bilirubin metabolism or clearance. Environmental and lifestyle influences, such as breastfeeding challenges or maternal diabetes, further exacerbate risk by altering hepatic function or gut motility. Ethnic and genetic predispositions, including enzyme deficiencies like Gilbert’s syndrome, also play a critical role in bilirubin regulation. Statistical disparities between full-term and preterm infants underscore the need for targeted screening and intervention strategies.

    High-Risk Groups and Their Vulnerabilities

    Vulnerable populations for neonatal jaundice are categorized based on biological, genetic, or perinatal factors that impair bilirubin processing or increase its production. Below is a structured overview of these groups, their risk factors, underlying mechanisms, and preventive measures.
    Group Risk Factor Why Vulnerable Prevention Methods
    Premature Infants Low gestational age (<37 weeks)
    • Immaturity of hepatic UDP-glucuronosyltransferase (UGT1A1) enzymes, reducing bilirubin conjugation.
    • Higher red blood cell (RBC) turnover due to shorter lifespan of fetal hemoglobin.
    • Decreased albumin levels, impairing bilirubin binding and transport.
    • Frequent monitoring of bilirubin levels via transcutaneous or serum testing.
    • Phototherapy initiation at lower thresholds (e.g., <12 mg/dL in preterm infants).
    • Early identification and treatment of sepsis or polycythemia.
    Infants with Blood Group Incompatibility Rh (D) or ABO incompatibility
    • Maternal antibodies (IgG) cross the placenta, targeting fetal RBCs, leading to hemolysis and elevated unconjugated bilirubin.
    • ABO incompatibility (e.g., mother O+, baby A+) causes milder but still significant hemolytic disease.
    • Rh incompatibility (e.g., Rh-negative mother, Rh-positive fetus) results in severe hemolysis if untreated.
    • Administration of Rh immune globulin (RhIG) to Rh-negative mothers during pregnancy/postpartum.
    • Intrauterine transfusion for severe fetal anemia detected via middle cerebral artery Doppler.
    • Exchange transfusion for newborns with bilirubin >20 mg/dL or signs of kernicterus.
    Infants with Genetic Conditions
    • Crigler-Najjar syndrome (Type I/II)
    • Gilbert’s syndrome
    • G6PD deficiency
    • Hereditary spherocytosis
    • Crigler-Najjar: Complete (Type I) or partial (Type II) deficiency of UGT1A1, leading to unconjugated hyperbilirubinemia.
    • Gilbert’s syndrome: Reduced UGT1A1 activity due to promoter polymorphism (*TA)7, causing mild, chronic jaundice.
    • G6PD deficiency: Hemolytic anemia triggered by oxidative stress (e.g., infections, fava beans), increasing bilirubin load.
    • Hereditary spherocytosis: RBC membrane defects cause premature destruction, elevating indirect bilirubin.
    • Genetic counseling and prenatal screening for high-risk families.
    • Phototherapy or phenobarbital (for Crigler-Najjar Type II) to induce UGT1A1.
    • Avoidance of oxidative triggers (e.g., sulfonamides) in G6PD-deficient infants.
    • Splenectomy for severe hereditary spherocytosis cases.
    Infants of Diabetic Mothers Gestational or pregestational diabetes
    • Fetal hyperinsulinemia suppresses erythropoietin, leading to polycythemia and increased RBC breakdown.
    • Delayed meconium passage reduces gut bacteria (e.g., E. coli), impairing enterohepatic circulation of bilirubin.
    • Hypoxia and acidosis in diabetic fetuses accelerate RBC hemolysis.
    • Tight glycemic control during pregnancy to reduce fetal complications.
    • Early feeding (breast or formula) to stimulate bowel movements and bilirubin excretion.
    • Partial exchange transfusion if bilirubin exceeds safety thresholds.

    Environmental and Lifestyle Factors Influencing Jaundice Risk

    Exogenous factors significantly modulate neonatal jaundice by altering bilirubin production, conjugation, or excretion. These include breastfeeding practices, delayed meconium passage, and maternal conditions that disrupt hepatic or gastrointestinal function. Below is a cause-effect analysis of key environmental contributors, structured to facilitate visualization via a flowchart.
    Central Mechanism: Disruption in bilirubin metabolism → Accumulation of unconjugated bilirubin → Jaundice progression.
    • Breastfeeding Challenges Breast milk jaundice (BMJ) occurs in 1–5% of breastfed infants due to:
      • Presence of β-glucuronidase in breast milk, which deconjugates bilirubin glucuronides in the gut, reabsorbing bilirubin into the circulation.
      • Inadequate milk intake leading to delayed meconium passage and reduced stooling, prolonging enterohepatic circulation.
      • Hormonal factors (e.g., prolactin) that may transiently reduce UGT1A1 activity.
      Key Indicator: Jaundice peaks at 7–14 days (later than physiological jaundice) and resolves without intervention by 3 weeks.
    • Delayed First Stool (Meconium Retention) Meconium contains high concentrations of bilirubin glucuronides; its delayed excretion (beyond 24–48 hours) increases reabsorption risk. Causes include:
      • Hypothyroidism (reduced gut motility).
      • Dehydration or insufficient feeding.
      • Maternal medications (e.g., opioids) crossing the placenta.
      Intervention: Early initiation of feeding (colostrum or formula) and monitoring for passage within 48 hours.
    • Maternal Diabetes and Obesity Maternal hyperglycemia induces fetal hyperinsulinemia, which:
      • Increases RBC mass and turnover, elevating bilirubin production.
      • Delays hepatic enzyme maturation due to altered placental nutrient transport.
      • Associates with macrosomia, complicating postnatal jaundice management.
      Statistical Link: Infants of diabetic mothers have a 2–3x higher risk of jaundice requiring phototherapy.
      • <

      what is jaundice in babies - Ilustrasi 3

      Diagnosis Methods and Medical Testing in Neonatal Jaundice

      The accurate diagnosis of jaundice in newborns relies on a structured, multi-step approach combining clinical assessment, laboratory testing, and predictive tools. Early and precise identification is critical to differentiate physiological jaundice from pathological conditions requiring intervention. Diagnostic methods range from non-invasive visual techniques to quantitative bilirubin measurements, with each modality offering distinct advantages in terms of accessibility, reliability, and clinical utility.

      The diagnostic process begins with visual inspection and progresses to objective testing, ensuring a balanced approach between simplicity and accuracy. Timing of tests is equally pivotal, as bilirubin levels fluctuate rapidly in the neonatal period, influencing treatment decisions such as phototherapy or exchange transfusion.

      Step-by-Step Diagnostic Process

      Diagnosis of neonatal jaundice follows a systematic progression, starting with subjective clinical signs and advancing to objective laboratory confirmation. This tiered approach minimizes unnecessary interventions while ensuring severe cases are identified promptly.
      1. Visual Assessment (Blanching Test)
        The initial evaluation involves observing skin and scleral (white of the eye) discoloration. A standardized technique, the blanching test, is performed by applying gentle pressure to the newborn’s skin with a finger or a gloved thumb. If the skin beneath the pressure point appears pale while the surrounding area remains yellow, jaundice is confirmed. This method is qualitative and does not quantify bilirubin levels but serves as a screening tool.
        Note: The blanching test is less reliable in darker-skinned infants, where jaundice may be harder to detect visually.
      2. Transcutaneous Bilirubin Measurement (TCB)
        When jaundice is suspected, a non-invasive device called a transcutaneous bilirubin (TCB) meter is used to estimate total serum bilirubin (TSB) levels. The meter emits light at specific wavelengths that penetrate the skin, and the reflected light is analyzed to calculate bilirubin concentration. This method is rapid, painless, and avoids the need for blood sampling in many cases.
      3. Serum Bilirubin Testing
        If TCB results fall within a borderline range or clinical suspicion remains high, a venous or capillary blood sample is drawn for direct serum bilirubin measurement. This gold-standard test provides precise TSB levels and distinguishes between conjugated (direct) and unconjugated (indirect) bilirubin, aiding in the differentiation of physiological from pathological jaundice.
        Standard Reference Range for Neonatal Jaundice (Term Infants):
        • Mild: 5–12 mg/dL (85–205 µmol/L)
        • Moderate: 12–15 mg/dL (205–256 µmol/L)
        • Severe: >15 mg/dL (>256 µmol/L)
      4. Additional Laboratory Investigations
        In cases of prolonged or severe jaundice, further tests may include:
        • Complete blood count (CBC) to rule out hemolytic anemia.
        • Blood group and Coombs test to identify Rh or ABO incompatibility.
        • Liver function tests (LFTs) to assess hepatic dysfunction.
        • Infection screening (e.g., TORCH panel for congenital infections).
      5. Timing of Diagnostic Tests
        Bilirubin levels peak at different times depending on gestational age. For term infants, testing is typically recommended at 24–48 hours of life, with follow-up measurements if levels remain elevated. Preterm infants may require earlier and more frequent monitoring due to their higher susceptibility to severe jaundice.

      Comparison of Transcutaneous Bilirubin (TCB) and Serum Bilirubin Testing

      The choice between TCB and serum bilirubin testing depends on clinical context, resource availability, and the need for precision. Below is a comparative analysis of these methods:
      Parameter Transcutaneous Bilirubin (TCB) Serum Bilirubin Test
      Invasiveness Non-invasive; no blood draw required. Invasive; requires venous or capillary blood sampling.
      Accuracy Estimates TSB with ±2–3 mg/dL variability; less accurate in darker skin tones or high bilirubin levels (>15 mg/dL). Gold standard; provides exact TSB and direct bilirubin levels.
      Cost Lower cost per test; no consumables (e.g., needles, tubes). Higher cost due to laboratory processing and disposal of biohazard materials.
      Turnaround Time Immediate results (seconds to minutes). Delayed (minutes to hours, depending on lab workflow).
      Clinical Utility Ideal for screening and serial monitoring in low-risk infants. Essential for confirming severe jaundice, guiding treatment, and diagnosing underlying causes.
      Limitations Reduced accuracy in preterm infants, those with high bilirubin, or skin conditions (e.g., bruising, edema). Invasive; risk of pain, infection, or anemia from repeated sampling.

      Role of Nomograms in Predicting Jaundice Severity

      Nomograms are graphical tools that integrate gestational age, postnatal age, and bilirubin levels to predict the risk of severe hyperbilirubinemia. Two widely used nomograms—Bhutani and Kramer—provide risk-stratified thresholds for intervention. These tools are particularly valuable in resource-limited settings where laboratory access is delayed.
      Example: Bhutani Nomogram (2004) The Bhutani nomogram plots hour-specific bilirubin risk zones for term and late-preterm infants. The axes include:
      • X-axis: Postnatal age in hours (0–144 hours).
      • Y-axis: Total serum bilirubin (TSB) in mg/dL (5–20 mg/dL).
      • Risk Zones:
        1. Zone I (Low Risk): Bilirubin levels below treatment thresholds.
        2. Zone II (Intermediate Risk): Levels approaching intervention criteria; requires close monitoring.
        3. Zone III (High Risk): Levels exceeding safe limits, necessitating immediate phototherapy or exchange transfusion.
      Interpretation: An infant with a TSB of 14 mg/dL at 48 hours of life in Zone III would trigger urgent intervention, whereas the same level in Zone II would warrant repeated testing within 6 hours.
      For preterm infants, the Kramer nomogram adjusts for lower gestational age thresholds, as these neonates are at higher risk for kernicterus even at lower bilirubin concentrations. Both nomograms are updated periodically to reflect evolving clinical evidence.

      Decision-Tree Framework for Timing and Treatment Based on Bilirubin Levels

      The timing of diagnostic tests and subsequent treatment decisions are governed by bilirubin trajectories and infant-specific risk factors. Below is a simplified decision-tree structure to illustrate how test results inform clinical action:
      Step 1: Initial Assessment (0–24 Hours)
      • Perform visual inspection and blanching test. • If jaundice detected, measure TCB at 24 hours.
      Step 2: TCB Results at 24 Hours
      • TCB ≤ Treatment Threshold:
      FAQ

      what is jaundice in babies caused by?

      Q: What causes jaundice in babies?

      what is jaundice in babies treatment?

      Q: What is the treatment for jaundice in babies?

      what is jaundice in babies how to treat?

      Q: How can you treat jaundice in babies at home?

      what is jaundice in babies eyes?

      Q: Does jaundice in babies affect their eyes?

      what is jaundice in babies blue light?

      Q: Why do babies with jaundice need blue light therapy?

      what is yellow jaundice in babies?

      Q: What is yellow jaundice in babies?

      Leave a Comment

      Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.